STERIS (NYSE:STE – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
STE has been the topic of several other reports. Weiss Ratings upgraded STERIS from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Morgan Stanley raised STERIS from an “overweight” rating to a “buy” rating in a research report on Friday. KeyCorp increased their price target on STERIS from $269.00 to $284.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. UBS Group decreased their price objective on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, Jefferies Financial Group upgraded STERIS from a “hold” rating to a “buy” rating and boosted their price objective for the company from $232.00 to $305.00 in a research note on Friday. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus price target of $283.50.
Check Out Our Latest Analysis on STE
STERIS Stock Down 0.2%
Shares of NYSE:STE opened at $263.76 on Friday. The company has a market capitalization of $25.61 billion, a PE ratio of 31.29 and a beta of 0.86. The business has a fifty day moving average price of $223.28 and a two-hundred day moving average price of $224.61. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.05 and a quick ratio of 1.44. STERIS has a 1 year low of $195.14 and a 1 year high of $269.44.
STERIS (NYSE:STE – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $2.94 EPS for the quarter, topping the consensus estimate of $2.68 by $0.26. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the previous year, the firm posted $2.47 earnings per share. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts forecast that STERIS will post 11.46 earnings per share for the current year.
Insiders Place Their Bets
In other STERIS news, CFO Karen L. Burton sold 5,880 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $255.62, for a total value of $1,503,045.60. Following the completion of the transaction, the chief financial officer owned 12,956 shares in the company, valued at $3,311,812.72. This trade represents a 31.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mohsen Sohi sold 4,893 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $253.22, for a total value of $1,239,005.46. Following the completion of the transaction, the director owned 24,305 shares of the company’s stock, valued at approximately $6,154,512.10. This represents a 16.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.12% of the company’s stock.
Institutional Investors Weigh In On STERIS
A number of institutional investors and hedge funds have recently modified their holdings of STE. Wellington Management Group LLP increased its holdings in shares of STERIS by 21.9% in the 2nd quarter. Wellington Management Group LLP now owns 3,502,897 shares of the medical equipment provider’s stock worth $737,605,000 after buying an additional 629,532 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of STERIS by 25.7% during the 1st quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock worth $411,995,000 after acquiring an additional 380,504 shares during the last quarter. Amundi grew its position in STERIS by 43.2% in the first quarter. Amundi now owns 771,092 shares of the medical equipment provider’s stock worth $170,512,000 after acquiring an additional 232,520 shares in the last quarter. SEB Asset Management AB purchased a new position in STERIS in the first quarter worth $30,660,000. Finally, Hsbc Holdings PLC grew its position in STERIS by 352.5% in the first quarter. Hsbc Holdings PLC now owns 176,320 shares of the medical equipment provider’s stock worth $38,958,000 after acquiring an additional 137,355 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.
About STERIS
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
Recommended Stories
- Five stocks we like better than STERIS
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
